Compare Hyatt Hotels Corporation (H) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Mesoblast Limited — how do they compare? Hyatt Hotels Corporation trades at $161.94 (market cap $15.02B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Hyatt Hotels Corporation is far larger — about 8.6× Mesoblast Limited's market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Mesoblast Limited for 15 Days on average.
| H | MESO | |
|---|---|---|
Market Cap | $15.02B | $1.75B |
Volume | 842,340 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $20.96 |
52-Week Low | $135.42 | $13.19 |
Typical Hold Time | 148 Days | 15 Days |
Enterprise Value | $18.93B | $1.83B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corporation (H) trades at $159.43, up 1.46% today, with a neutral technical stance and mixed fundamentals. The stock has beaten earnings estimates for three consecutive quarters, but profitability metrics remain thin with a net margin of 1.1% and elevated P/E of 196.83. Recent news highlights brand expansion and a strategic loyalty collaboration with Delta Air Lines, signaling growth initiatives amid a challenging profit environment.
The outlook balances growth potential from fee expansion and new partnerships against high valuation and earnings volatility. Risks include project delays, debt levels, and regional economic sensitivity. Analyst consensus is a Moderate Buy with a $197.77 price target, suggesting 24% upside, but investors face headwinds from margin pressure and competitive dynamics in the hospitality sector.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
